We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Arteris
AIP
$1.03B
| $60.1K | ﹤0.01% |
8,000
-2,000
| -20% | -$15.2K |
|
1602
Labcorp
LH
$26.2B
| $59.6K | ﹤0.01% |
293
-20
| -6% | -$4.07K |
|
1603
Waters Corp
WAT
$41.6B
| $59.5K | ﹤0.01% |
+205
| New | +$65.4K |
|
1604
Innovative Industrial Properties
IIPR
$1.55B
| $58.8K | ﹤0.01% |
538
+312
| +138% | +$32.8K |
|
1605
Keurig Dr Pepper
KDP
$43.2B
| $58.7K | ﹤0.01% |
1,757
+314
| +22% | +$10.4K |
|
|
CFB
1606
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
| $58.5K | ﹤0.01% |
4,175
-410
| -9% | -$5.3K |
|
1607
Advantage Solutions
ADV
$428M
| $58.5K | ﹤0.01% |
727
-189
| -21% | -$17.6K |
|
1608
ProKidney
PROK
$380M
| $57.3K | ﹤0.01% |
23,303
-89,983
| -79% | -$242K |
|
1609
Textron
TXT
$14B
| $55.9K | ﹤0.01% |
651
-533
| -45% | -$47.4K |
|
1610
EQT Corp
EQT
$31.7B
| $55.8K | ﹤0.01% |
1,510
-794
| -34% | -$31.1K |
|
1611
Sanmina
SANM
$10.6B
| $53.1K | ﹤0.01% |
801
+2
| +0.3% | +$128 |
|
1612
Northwest Natural Holdings
NWN
$2.04B
| $52.6K | ﹤0.01% |
1,457
-194
| -12% | -$7.17K |
|
1613
TransUnion
TRU
$14.5B
| $52.3K | ﹤0.01% |
705
-826
| -54% | -$61.6K |
|
1614
Factset
FDS
$9.8B
| $51.9K | ﹤0.01% |
+127
| New | +$54K |
|
1615
Cognizant
CTSH
$28.1B
| $51.4K | ﹤0.01% |
756
-3,033
| -80% | -$206K |
|
1616
CVR Energy
CVI
$5.36B
| $51.1K | ﹤0.01% |
1,908
-4,426
| -70% | -$134K |
|
1617
Deluxe
DLX
$1.09B
| $50.8K | ﹤0.01% |
2,262
+811
| +56% | +$17.3K |
|
1618
International Paper
IP
$18B
| $50.7K | ﹤0.01% |
1,174
-360,809
| -100% | -$14.7M |
|
1619
APi Group
APG
$16B
| $49.1K | ﹤0.01% |
1,959
-267
| -12% | -$6.7K |
|
1620
Extra Space Storage
EXR
$29B
| $48.6K | ﹤0.01% |
313
-1,276
| -80% | -$186K |
|
|
SBDS
1621
DELISTED
Solo Brands Inc
SBDS
| $48.6K | ﹤0.01% |
533
+123
| +30% | +$9.69K |
|
1622
Fabrinet
FN
$14B
| $47.7K | ﹤0.01% |
195
-33
| -14% | -$7K |
|
1623
Robert Half
RHI
$3.8B
| $44.9K | ﹤0.01% |
702
-2,223
| -76% | -$153K |
|
|
HBI
1624
DELISTED
Hanesbrands
HBI
| $44.2K | ﹤0.01% |
8,963
+1
| +0% | +$5 |
|
1625
Ingles Markets
IMKTA
$1.56B
| $44.1K | ﹤0.01% |
643
-3,426
| -84% | -$248K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.